These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32342128)

  • 1. Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.
    Belounis A; Ayoub M; Cordeiro P; Lemieux W; Teira P; Haddad E; Herblot S; Duval M
    Cancer Immunol Immunother; 2020 Sep; 69(9):1767-1779. PubMed ID: 32342128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.
    Cordeau M; Belounis A; Lelaidier M; Cordeiro P; Sartelet H; Herblot S; Duval M
    PLoS One; 2016; 11(10):e0164401. PubMed ID: 27716850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.
    Díaz-Rodríguez Y; Cordeiro P; Belounis A; Herblot S; Duval M
    Cancer Immunol Immunother; 2017 Oct; 66(10):1307-1320. PubMed ID: 28555259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
    Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
    Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.
    Valteau-Couanet D; Leboulaire C; Maincent K; Tournier M; Hartmann O; Bénard J; Beaujean F; Boccaccio C; Zitvogel L; Angevin E
    Blood; 2002 Oct; 100(7):2554-61. PubMed ID: 12239169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells.
    Romagnani C; Della Chiesa M; Kohler S; Moewes B; Radbruch A; Moretta L; Moretta A; Thiel A
    Eur J Immunol; 2005 Aug; 35(8):2452-8. PubMed ID: 15997468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
    Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
    Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.